A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 117 participants.
Also called NCT07192952
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 117 participants
- Sponsor
- Registry
-
NCT07192952 -
2024-519830-22-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Finland, Germany, Greece, Hungary, Israel, Italy, Mexico, Poland, Portugal, South Korea, Spain, Sweden, Taiwan, Türkiye, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07192952. Allocation not applicable; no masking; primary purpose treatment. Start 2026-06-01 (actual); primary completion 2030-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
- Acronym
- FIORELLO
- Condition
- Left Ventricular Systolic Dysfunction
- Condition
- Heart Failure (Pediatric)
- Intervention (Drug)
- Finerenone (Kerendia, BAY94-8862)
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct07192952- Content hash
1d06945bf64dbc2084bdb636a3d65ffd517ff304273029c0ad831cd214d414ee